An agreement has been announced, which will result in the expansion of kinase profiling and assay development in the pharmaceutical and biotech industries.
The deal between Japanese biotechnology company Carna Biosciences and Caliper Life Sciences of the US will see Carna have more influence in the area of kinase inhibitor drug discovery – a major focus of targeted therapy in the areas of cancer, neurological and autoimmune diseases.
“I am proud of the expression and purification technologies that Carna has developed in order to produce nearly 300 human kinases to date, and even more pleased that Caliper has selected Carna Biosciences as a principle supplier for Caliper’s ProfilerPro Kits,” said Kohichiro Yoshino, Carna’s president.
The agreement will give Carna new opportunities to expand sales of protein kinases worldwide. “This synergistic impact of combining Caliper’s advanced instrumentation with the wide selection and premier quality reagents provided by Carna will greatly benefit both companies and their clients,” Mr Yoshino added.
“We anticipate that this expanded relationship with Caliper will further position us to explore research and development partnerships with global biopharmaceutical companies.”
Carna specialises in conducting intercellular signalling-based drug discovery programmes, as well as providing drug discovery services to pharmaceutical companies.
Copyright PA Business 2008